Evelo Biosciences, Inc. Common Stock
EVLO
EVLO was delisted on the 11th of December, 2023.
38 hedge funds and large institutions have $258M invested in Evelo Biosciences, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 19 increasing their positions, 8 reducing their positions, and 2 closing their positions.
138% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 8
13% more capital invested
Capital invested by funds: $229M → $258M (+$28.9M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less funds holding
Funds holding: 41 → 38 (-3)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$344K |
| 2 |
Nuveen
Charlotte,
North Carolina
|
+$298K |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$148K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$133K |
| 5 |
State Street
Boston,
Massachusetts
|
+$132K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$189K |
| 2 |
Jane Street
New York
|
-$146K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$55K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$37.7K |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$18K |
EVLO Hedge Fund Activity: Q2 2019 in Review
38 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Evelo Biosciences, Inc. Common Stock (EVLO) for Q2 2019, worth a combined $258M — up 13% from $229M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of EVLO and 1 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 19 added.
The largest buyer was Fidelity Investments, adding an estimated $344K. The largest seller was Victory Capital Management, cutting an estimated $189K.
- 38 institutional investors held Evelo Biosciences, Inc. Common Stock (EVLO) as of Q2 2019, down from 41 in Q1 2019.
- Funds reported $258M of Evelo Biosciences, Inc. Common Stock stock for Q2 2019, up 13% quarter-over-quarter.
- 1 fund opened new Evelo Biosciences, Inc. Common Stock positions in Q2 2019 and 2 closed out, a net change of -1 holder.
- The largest Evelo Biosciences, Inc. Common Stock buyer in Q2 2019 was Fidelity Investments, an estimated $344K added.
- The largest Evelo Biosciences, Inc. Common Stock seller in Q2 2019 was Victory Capital Management, an estimated $189K sold.
Based on aggregated 13F filings for Q2 2019.